996 related articles for article (PubMed ID: 28297624)
21. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
22. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
23. Somatic mutations precede acute myeloid leukemia years before diagnosis.
Desai P; Mencia-Trinchant N; Savenkov O; Simon MS; Cheang G; Lee S; Samuel M; Ritchie EK; Guzman ML; Ballman KV; Roboz GJ; Hassane DC
Nat Med; 2018 Jul; 24(7):1015-1023. PubMed ID: 29988143
[TBL] [Abstract][Full Text] [Related]
24. Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia.
Parkin B; Ouillette P; Yildiz M; Saiya-Cork K; Shedden K; Malek SN
Clin Cancer Res; 2015 May; 21(9):2045-56. PubMed ID: 25652455
[TBL] [Abstract][Full Text] [Related]
25. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
Falini B; Martelli MP
Best Pract Res Clin Haematol; 2015; 28(2-3):90-7. PubMed ID: 26590764
[TBL] [Abstract][Full Text] [Related]
26. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
27. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
[TBL] [Abstract][Full Text] [Related]
28. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
29. New insights in AML biology from genomic analysis.
Perry AM; Attar EC
Semin Hematol; 2014 Oct; 51(4):282-97. PubMed ID: 25311741
[TBL] [Abstract][Full Text] [Related]
30. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Nardi V; Hasserjian RP
Surg Pathol Clin; 2016 Mar; 9(1):143-63. PubMed ID: 26940274
[TBL] [Abstract][Full Text] [Related]
31. The complexity of interpreting genomic data in patients with acute myeloid leukemia.
Nazha A; Zarzour A; Al-Issa K; Radivoyevitch T; Carraway HE; Hirsch CM; Przychodzen B; Patel BJ; Clemente M; Sanikommu SR; Kalaycio M; Maciejewski JP; Sekeres MA
Blood Cancer J; 2016 Dec; 6(12):e510. PubMed ID: 27983727
[TBL] [Abstract][Full Text] [Related]
32. Genetic mutations in acute myeloid leukemia that influence clinical decisions.
Chung SS
Curr Opin Hematol; 2014 Mar; 21(2):87-94. PubMed ID: 24445361
[TBL] [Abstract][Full Text] [Related]
33. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
34. Acute Myeloid Leukemia With Recurrent Genetic Abnormalities Other Than Translocations.
Lin P; Falini B
Am J Clin Pathol; 2015 Jul; 144(1):19-28. PubMed ID: 26071459
[TBL] [Abstract][Full Text] [Related]
35. Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.
Castelli G; Pelosi E; Testa U
Onco Targets Ther; 2018; 11():131-155. PubMed ID: 29343972
[TBL] [Abstract][Full Text] [Related]
36. Clonal hierarchy of main molecular lesions in acute myeloid leukaemia.
Herudkova Z; Culen M; Folta A; Jeziskova I; Cerna J; Loja T; Tom N; Smejkal J; Semerad L; Dvorakova D; Mayer J; Racil Z
Br J Haematol; 2020 Aug; 190(4):562-572. PubMed ID: 31822038
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia.
Hartmann L; Nadarajah N; Meggendorfer M; Höllein A; Vetro C; Kern W; Haferlach T; Haferlach C; Stengel A
Leukemia; 2020 Mar; 34(3):811-820. PubMed ID: 31719678
[TBL] [Abstract][Full Text] [Related]
38. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn N; Terzer T; Sträng E; Dolnik A; Cocciardi S; Panina E; Corbacioglu A; Herzig J; Weber D; Schrade A; Götze K; Schröder T; Lübbert M; Wellnitz D; Koller E; Schlenk RF; Gaidzik VI; Paschka P; Rücker FG; Heuser M; Thol F; Ganser A; Benner A; Döhner H; Bullinger L; Döhner K
Blood Adv; 2020 Dec; 4(24):6342-6352. PubMed ID: 33351131
[TBL] [Abstract][Full Text] [Related]
39. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
40. Persistence of DNMT3A mutations at long-term remission in adult patients with AML.
Pløen GG; Nederby L; Guldberg P; Hansen M; Ebbesen LH; Jensen UB; Hokland P; Aggerholm A
Br J Haematol; 2014 Nov; 167(4):478-86. PubMed ID: 25371149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
